**Original Research Article**

****

**PATHOLOGIES OF THE ELDERLY AND PHARMACOTHERAPY IN THE HEALTH AREA OF BIWONG-BANE, SOUTH CAMEROON**

**ABSTRACT**

**Objectives**: The specific characteristics of the elderly physiopathology, such as polypathology and polypharmacy, arouse interest in the quality of the care offered to this age group. The study aimed to analyse the gap between the pathological and  therapeutic profiles at the local level in Cameroon.

**Method**: This was a six-month cross-sectional situational analysis at the Biwong-Bane District Medical Centre in the South region of Cameroon. Pathological data were collected from the consultation register, and those related to therapeutics were taken from the drug inventory lists for the period of July 2019 to July 2020, using two separate reading grids. The 20th version of Statistical Package for the Social Sciences software was used for the analysis of the data set.

**Results**: For a total of 103 patient files, the mean age was 68.6±7.7 years with a sex ratio of 0.75. 21.7% of the population was aged ≥ 75 years. The main pathology groups were infectious diseases (40%) and diseases of the osteoarticular system (16.4%). Out the 140 occurrences counted, malaria, typhoid fever and high blood pressure were the most common at 26, 12 and 7 respectively. Polypathologies represented 28.2% of the sample. With regard to therapeutics, there was a concordance between prescriptions and available drugs, although stock-outs persisted, as with artesunate (10 months) and mineral supplements (6 months). Finally, the average number of active molecules administered per elderly person ≥75 years was 3.47.

**Conclusion**: The pharmacotherapy provided to the Third age remains poorly adapted, mainly due to the unavailability of drugs specific to the needs of this population.

**Keywords**: Pathologies of the Third age, pharmacotherapy, elderly patient, South Cameroon.

**INTRODUCTION**

In 2017, the World Health Organisation (WHO) estimated that the number of people in the Third age group (60 years and older) would increase from 900 million to 2 billion worldwide by 20501. With the emergence of the Covid-19 pandemic and its specific risks for this population, namely higher mortality rates, neglect and poor treatment having a major impact on their economic and social well-being2, this global trend remains somewhat of a public health concern in many respects. Although ~~african~~ countries remain less affected, there is a significant demand for quality health care for non-Covid-19 related conditions. In terms of clinical management, the senescence that characterises the elderly describes a polypathology in which comorbidities and polypharmacy coexist, and which requires appropriate pharmacotherapy in order to ensure the safety of drug treatments. It is also a question of ensuring a continuous supply of essential medicines, particularly in areas of difficult geographical access, to compensate for stock shortages of varying lengths in the pharmacies of the health facilities that cover these areas3,4. While the question of the quality of the drug management system for the elderly remains poorly documented, this research focuses on the availability and adequacy of the drug prescriptions with respect to the target population pathological profile in order to improve the primary care supply at the local level in Cameroon.

**METHOD**

A cross-sectional situational analysis was conducted at the Biwong-Bane District Medical Centre in the South Cameroon Region for six (06) months. This is the main health facility in the area and receives almost all the local patients. The study population consisted of files of patients aged 60 years and over, treated as outpatients and/or inpatients. Any file with incomplete and/or illegible information for the investigator was excluded. The sampling was exhaustive. The collection period for pathological and therapeutic data was one (01) year, from July 2019 to July 2020. It consisted of the collection, by means of a reading grid, of four (04) items, namely age, sex, diagnosis and drug prescription; via the patient consultation register. The pathologies were presented according to the 10th edition of the WHO's International Statistical Classification of Diseases and Related Health Problems (ICD-10)5. With regard to the availability of therapy, the inventory lists from the collection period were used to identify the gaps between the needs expressed and the inputs provided, in terms of adequacy and physical accessibility. A reading grid was used to specify the therapeutic classes according to the current National List of Essential Medicines (NLEM)6, thus making it possible to exclude those not specific to the target and/or associated with particular conditions (paediatrics and pregnancy). The statistical analysis of the data was carried out using Statistical Package for the Social Sciences software 20, and the data were reported in terms of numbers, frequencies, averages ± deviations and extremes.

This study was previously evaluated by the Institutional Ethics and Research Committee of the Faculty of Medicine and Biomedical Sciences of the University of Yaounde I, which granted it an ethical clearance. Data collection in the field was initiated after authorization from the head of the targeted health structure. In addition, the principle of confidentiality was duly respected.

**RESULTS AND DISCUSSION**

**Sociodemographic data**

Consultations for the elderly accounted for 14.8% of total consultations with 39 hospitalizations. The final sample consisted of 103 files. The sex ratio was 0.75. The average age was 68.6 ± 7.7 years, with extremes of 60 and 95 years. Nearly 78.3% of the patients were aged ≤ 75 years, with a predominance of females (56.25%).

**Pathological profile**

This research reveals a sparse pathological picture. According to ICD-10, only 13 chapters were represented. Chapter I: Certain infectious and parasitic diseases (malaria and typhoid fever), and Chapter XIII: Diseases of the osteoarticular system, musculature and connective tissue (lumbar osteoarthritis and pain), were the majority classes at 40% and 16.4% respectively. Similar results found in Senegal revealed that, out of 1,145 elderly people received in the health facilities studied, 31.2% suffered from infectious diseases, 15.1% from cardiovascular diseases, 10.5% from osteoarticular diseases, and 9.1% from digestive diseases. This is essentially linked, on the one hand, to the epidemiological profile of the sub-region, which shows a high proportion of malaria and infectious intestinal diseases, and on the other hand, to the physiopathology and lifestyle of the elderly themselves. The distribution of pathologies according to sex is illustrated by a predominance of cases of elderly women in groups of more than 10 (Chapters I, IX, XI and XIII), with a difference of up to 51.2% for Chapter I. This is illustrated in the figure below.

 **Figure 1 : ICD-10 disease groups by gender**

Furthermore, this classification resulted in a total number of 60 diseases. The main one being malaria in its simple and severe forms, as described in the following table.

**Table 1: Most common pathologies (more than 5 cases)**

|  |  |  |
| --- | --- | --- |
| **Designation** | **Number of cases (N=140)** | **Percentage** |
| Malaria | 26 | 18,6~~%~~ |
| Typhoid fever | 12 | 8,6~~%~~ |
| High blood pressure | 7 | 5~~%~~ |
| Inguinal hernia | 6 | 4,3~~%~~ |
| Lombar osteoarthritis | 6 | 4,3~~%~~ |
| Urinary tract infection  | 5 | 3,6~~%~~ |
| Lombosciatica | 5 | 3,6~~%~~ |
| Others pathologies | 73 | 52,1~~%~~ |

*N= Total number of cases*

Polypathological patients (with concomittant diseases) represented 28.2% of the sample. Those aged 75 and more were the most affected, at 41.4%.

**Drug therapy**As regards drug therapy, the drug prescriptions were matched to the diagnoses made. Thus, for each disease group, at least one prescribed drug was available in stock. According to the current NLEM, there were 30 therapeutic classes available during the research period.  Antibacterials (18.9%), vitamins and minerals (8.1%), antimalarials (6.8%), anaesthetics (5.4%), and non-steroidal anti-inflammatory drugs (5.4%) were the most represented. However, supply disruptions were observed for 4 active molecules, including mineral supplements, but also artesunate and artemether in injectable form, which are recommended as first and second line treatment for severe malaria8. Other drugs were affected by these stock-outs as detailed in **Table 2**.

**Table 2: Active molecules out of stock**

|  |  |  |
| --- | --- | --- |
| **INN** | **Pharmaceutical form** | **Duration of break** |
| Artesunate | injectable | 10 months and more |
| Calcium | tablet | 6 months and more |
| Magnesium | tablet | 6 months and more |
| Diclofenac | injectable | 30 days |
| Artemether | injectable | 20 days |

*INN= International Nonproprietary Names*

The reasons for stock-outs are associated with the inefficiency of the supply chain (Type of supply, suppliers, transit, etc.) and with a lack of financial resources allocated to the purchase of medicines. These bottlenecks are specific to health facilities at local level (Health centres, District medical centres and District hospitals) located in areas of difficult geographical access, as reported in some studies3,9. This is further complicated when dealing with a special needs population.

Although polypathology and adjacent polypharmacy increase with age, it is necessary to monitor for the development of iatrogenic pathological effects that cause complications. It is noted that 39 out of 103 elderly people had been hospitalized, which implies that more than half had received their care on an outpatient basis, thus making therapeutic follow-up difficult. This poses the limitation of collecting data related to iatrogeny. Nevertheless, research conducted in internal medicine departments in Cameroon showed that polymedication was a risk factor for the occurrence of iatrogenic events in the elderly10. And because polypharmacy complicates therapeutic strategies, monitoring and compliance with treatment, the French National Authority for Health recommends that, on average, daily consumption should be 3.6 drugs over the age of 65, 4 drugs between the ages of 75 and 84, and 4.6 after the age of 8511. Drug interactions and pharmacological changes in certain molecules should also be taken into account12. During the study period, no iatrogenic events were recorded in the patients' files. The average number of active molecules received was 3.47 in the over 75s with an extreme of 6 for 1 patient aged 80.

Ultimately, the sample size here, characterised by the category of health facility and its geographical location, can be considered a limitation of the study. Indeed, although the data resulting from this research are sufficient for extrapolation under similar conditions, they are not representative for a study on the systemic management of diseases of the Third age on a national scale.

**Statistical analysis**

**CONCLUSION**

The drug management of the elderly diseases at local level is far from optimal. The variety of care needs and the complexity of this management requires a multidisciplinary approach, in which prescribers and providers collaborate with the informed involvement of the patient, in order to ensure the availability of the therapy and to mitigate any adverse iatrogenic event.

**ACKNOWLEDGEMENTS**

We would like to thank the medical team of the Biwong-Bane District Medical Centre for their welcome and availability.

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest.

**AUTHORS CONTRIBUTION**

The study was designed and conducted in collaboration of all the authors. They declare that they have wrote and approved the present manuscript.

**REFERENCES**

1. Organisation Mondiale de la Santé (OMS). 10 faits sur le vieillissement et la santé   [Internet]. 2017. <https://www.who.int/features/factfiles/ageing/fr/> Accessed 17 Nov 2020.

2.  Nations Unies (UN). Note de synthèse : L’impact de la COVID-19 sur les personnes âgées. UN; 2020. p. 2-3

3.  Edo’o V.D. Système d’approvisionnement en médicaments à Bengbis, Djoum et Mintom au Sud-Cameroun [Résumé de thèse]. Health Sci Dis; Juin 2018. <https://www.hsd-fmsb.org/index.php/hsd/thesis/view/666>

4. Tchoukouagneu F. Vieillesse et accès aux soins de santé au Cameroun. Université de Liège; 2016 p. 11.

5. OMS. Classification statistique internationale des maladies et des problèmes de santé connexes, 10e révision. 2008th ed. Genève: OMS; 2009.

6. Ministère de la Santé Publique, Département de la Pharmacie, du Médicament et des Laboratoires. Liste nationale des médicaments et autres produits pharmaceutiques essentiels. Cameroun: Minsanté; 2017. p 4-42

7. Diallo I. Morbidité et prise en charge des maladies des personnes du troisième âge au Sénégal. 1998. (Amélioration de la prise en charge médicale des personnes du troisième âge).

8. Programme National de Lutte contre le Paludisme (PNLP). Guide de prise en charge du Paludisme à l’usage du personnel de santé. Yaoundé: Ministère de la Santé Publique; 2019. p. 34-5

9. Fonds Mondial. Processus de la chaîne d’approvisionnement du Fonds mondial pour les pays. Genève. Suisse: Fonds Mondial; 2017 Avril p. 40. Report No.: GF-OIG-17-008. 3.

10.    Ntsama MJ et al. Pathologies iatrogènes chez les sujets âgés hospitalisés dans les services de médecine interne au Cameroun : Une étude prospective. Health Sci Dis. 2018 Dec;19(4):84–8. https:// Doi : 10.1016/j.revmed.2018.03.261

11  Pfizer. Effets indésirables et sujet âgé : comment mieux prescrire ? [Internet]. PfizerPro. 2018. Disponible sur : <https://www.pfizerpro.fr/news/effets-indesirables-et-sujet-age-comment-mieux-prescrire> Accessed 16 Nov 2020

12.  Pelemans W. Le profil gériatrique. In Paris: Pfizer; 2019. p. 49–60.